The RAS gene is abnormally expressed in 30% to 50% of patients and is associated with shorter survival. Therefore, RAS may be a good treatment target in myeloma. This gene requires a modification to induce growth of the myeloma cells. The drug FTI inhibits the protein responsible for this modification, thereby interfering with the effects of RAS. The efficiency of this drug is currently being tested as part of a study in patients with advanced myeloma. The main objective of this proposal is to determine which drugs could be used with FTI to enhance its antimyeloma effect. These studies should provide the preclinical data for the development of future studies.